Track 4D Molecular Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

4D Molecular Therapeutics, Inc. FDMT Open 4D Molecular Therapeutics, Inc. in new tab

9.48 USD
EPS
-2.42
P/B
1.06
ROE
-27.57
Beta
3.01
Target Price
31.33 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 7, 2026
EPS-2.42
Book Value8.78
Price to Book1.06
Debt/Equity4.24
% Insiders3.612%
Growth
Revenue Growth85089.00%
Estimates
Forward P/E-2.46
Forward EPS-3.80
Target Mean Price31.33

DCF Valuation

Tweak assumptions to recompute fair value for 4D Molecular Therapeutics, Inc. (FDMT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

4D Molecular Therapeutics, Inc. Logo 4D Molecular Therapeutics, Inc. Analysis (FDMT)

United States Health Care Official Website Stock

Is 4D Molecular Therapeutics, Inc. a good investment? 4D Molecular Therapeutics, Inc. (FDMT) is currently trading at 9.48 USD. Market analysts have a consensus price target of 31.33 USD. This suggests a potential upside from current levels.

Earnings Schedule: 4D Molecular Therapeutics, Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is -3.80.

Investor FAQ

Does 4D Molecular Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is 4D Molecular Therapeutics, Inc.?

4D Molecular Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -2.42.

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Exchange Ticker
NMS (United States) FDMT

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion